201 related articles for article (PubMed ID: 11742322)
1. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
Morris KT; Toth-Fejel S; Schmidt J; Fletcher WS; Pommier RF
Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
3. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
4. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line.
Poulin R; Labrie F
Cancer Res; 1986 Oct; 46(10):4933-7. PubMed ID: 2944574
[TBL] [Abstract][Full Text] [Related]
6. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
7. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
8. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool.
Toth-Fejel S; Cheek J; Calhoun K; Muller P; Pommier RF
Arch Surg; 2004 Jan; 139(1):50-4. PubMed ID: 14718276
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in breast cancer therapy.
Brueggemeier RW
Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant.
Calhoun KE; Pommier RF; Muller P; Fletcher WS; Toth-Fejel S
Arch Surg; 2003 Aug; 138(8):879-83. PubMed ID: 12912747
[TBL] [Abstract][Full Text] [Related]
12. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors: new endocrine treatment of breast cancer.
Brueggemeier RW
Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
[TBL] [Abstract][Full Text] [Related]
14. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
15. Significance of aromatase activity in human breast cancer.
Miller WR; Hawkins RA; Forrest AP
Cancer Res; 1982 Aug; 42(8 Suppl):3365s-3368s. PubMed ID: 7083201
[TBL] [Abstract][Full Text] [Related]
16. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone sulfate estrogenic action at its physiological plasma concentration in human breast cancer cell lines.
Le Bail JC; Allen K; Nicolas JC; Habrioux G
Anticancer Res; 1998; 18(3A):1683-8. PubMed ID: 9673390
[TBL] [Abstract][Full Text] [Related]
18. The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression.
Calhoun K; Pommier R; Cheek J; Fletcher W; Toth-Fejel S
Am J Surg; 2003 May; 185(5):411-5. PubMed ID: 12727558
[TBL] [Abstract][Full Text] [Related]
19. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
[TBL] [Abstract][Full Text] [Related]
20. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
